Last reviewed · How we verify

Nerinetide (NA-1) — Competitive Intelligence Brief

Nerinetide (NA-1) (Nerinetide (NA-1)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor modulator / Neuroprotective peptide. Area: Neurology.

phase 3 NMDA receptor modulator / Neuroprotective peptide PSD-95 (postsynaptic density protein 95) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Nerinetide (NA-1) (Nerinetide (NA-1)) — NoNO Inc.. Nerinetide is a peptide that inhibits postsynaptic density protein 95 (PSD-95) to reduce excitotoxic neuronal death following ischemic stroke.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Nerinetide (NA-1) TARGET Nerinetide (NA-1) NoNO Inc. phase 3 NMDA receptor modulator / Neuroprotective peptide PSD-95 (postsynaptic density protein 95)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor modulator / Neuroprotective peptide class)

  1. NoNO Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nerinetide (NA-1) — Competitive Intelligence Brief. https://druglandscape.com/ci/nerinetide-na-1. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: